share_log

Repare Therapeutics (NASDAQ:RPTX) Shares Gap Down to $14.55

Financial News Live ·  Jan 6, 2023 12:01

Repare Therapeutics Inc. (NASDAQ:RPTX – Get Rating) shares gapped down prior to trading on Friday . The stock had previously closed at $14.55, but opened at $13.89. Repare Therapeutics shares last traded at $13.93, with a volume of 400 shares.

Analyst Ratings Changes

A number of analysts have recently issued reports on the stock. Capital One Financial initiated coverage on shares of Repare Therapeutics in a report on Friday. They set an "overweight" rating and a $28.00 price target for the company. HC Wainwright dropped their price target on shares of Repare Therapeutics from $38.00 to $25.00 and set a "buy" rating for the company in a research note on Thursday, November 17th. One analyst has rated the stock with a hold rating and five have assigned a buy rating to the company. Based on data from MarketBeat, the company has a consensus rating of "Moderate Buy" and an average target price of $30.80.

Get Repare Therapeutics alerts:

Repare Therapeutics Price Performance

The firm's 50-day simple moving average is $15.56 and its two-hundred day simple moving average is $13.94. The company has a market capitalization of $615.55 million, a price-to-earnings ratio of -19.93 and a beta of 0.11.

Repare Therapeutics (NASDAQ:RPTX – Get Rating) last issued its earnings results on Wednesday, November 9th. The company reported $1.71 earnings per share for the quarter, topping the consensus estimate of ($0.20) by $1.91. Repare Therapeutics had a negative net margin of 21.31% and a negative return on equity of 9.53%. The company had revenue of $112.55 million for the quarter, compared to analyst estimates of $43.23 million. On average, analysts expect that Repare Therapeutics Inc. will post -0.69 EPS for the current fiscal year.

Insider Activity at Repare Therapeutics

In related news, Director Davis Jerel sold 250,000 shares of the company's stock in a transaction that occurred on Friday, December 9th. The shares were sold at an average price of $16.00, for a total transaction of $4,000,000.00. Following the transaction, the director now owns 2,094,451 shares of the company's stock, valued at $33,511,216. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Insiders own 33.60% of the company's stock.

Hedge Funds Weigh In On Repare Therapeutics

A number of large investors have recently bought and sold shares of the stock. Deep Track Capital LP raised its stake in Repare Therapeutics by 26.9% during the first quarter. Deep Track Capital LP now owns 2,664,017 shares of the company's stock worth $37,936,000 after purchasing an additional 564,017 shares during the period. Affinity Asset Advisors LLC increased its position in shares of Repare Therapeutics by 72.5% in the first quarter. Affinity Asset Advisors LLC now owns 468,905 shares of the company's stock worth $6,677,000 after acquiring an additional 197,127 shares in the last quarter. BlackRock Inc. increased its position in shares of Repare Therapeutics by 1.9% in the first quarter. BlackRock Inc. now owns 467,311 shares of the company's stock worth $6,655,000 after acquiring an additional 8,680 shares in the last quarter. Sumitomo Mitsui Trust Holdings Inc. acquired a new stake in shares of Repare Therapeutics in the third quarter worth $2,269,000. Finally, Renaissance Technologies LLC increased its position in shares of Repare Therapeutics by 105.3% in the second quarter. Renaissance Technologies LLC now owns 180,900 shares of the company's stock worth $2,531,000 after acquiring an additional 92,800 shares in the last quarter. Hedge funds and other institutional investors own 78.19% of the company's stock.

About Repare Therapeutics

(Get Rating)

Repare Therapeutics Inc, a clinical-stage precision oncology company, discovers and develops therapeutics by using its synthetic lethality approach in Canada and the United States. The company uses its SNIPRx, a proprietary, genome-wide, and CRISPR-enabled platform to systematically discover and develop highly targeted cancer therapies that focuses on genomic instability, including DNA damage repair.

Featured Stories

  • Get a free copy of the StockNews.com research report on Repare Therapeutics (RPTX)
  • Four Undervalued Healthcare Stocks for 2023
  • WWE Stock: Vince McMahon Wants Back In The Show
  • NVIDIA Is Bottoming But Don't Buy It Just Yet
  • Is Your Portfolio Flexible Enough for FLEX Stock?
  • How 2022's Biggest Healthcare Gainers Could Fare In 2023

Receive News & Ratings for Repare Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Repare Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment